HCG for Men: Benefits, Uses, and Side Effects

For men weighing the hCG benefits for men conversation, the appeal is straightforward: human chorionic gonadotropin (hCG) behaves like luteinizing hormone (LH) and can prompt the testes to produce more of their own testosterone, rather than replacing it from the outside. That mechanism underpins its use in selected fertility and hormone scenarios. But the regulatory picture is nuanced — most popular “benefits for men” uses are off-label, and hCG used for those purposes is typically compounded and not FDA-approved. This article is educational information, not medical advice.

What is hCG and how does it work in men?

hCG and LH are heterodimeric glycoproteins that share a common alpha subunit and act on the same receptor — the LH/choriogonadotropin receptor (LHCGR) — activating the cAMP/PKA pathway in testicular Leydig cells to drive testosterone synthesis. Their beta subunits are roughly 80–85% homologous, according to a narrative review in Endocrine Reviews.

The practical difference is duration. hCG’s beta subunit carries a unique C-terminal peptide extension that gives it a much longer circulating half-life — about 34 hours, versus roughly 90 minutes for LH (Endocrine Reviews). That is why hCG is described as a long-acting LH analog: it substitutes for LH at the testis. In an in-vitro study using mouse Leydig cells, hCG was roughly 10-fold more potent than LH in recruiting cAMP, yet both produced equivalent downstream testosterone synthesis (PMC, preclinical) — a mechanism finding from animal cells, not a human clinical outcome.

What are hCG’s FDA-approved uses in men?

FDA-approved hCG products such as Pregnyl carry exactly two male indications on the label: (1) prepubertal cryptorchidism not due to anatomical obstruction, and (2) selected cases of hypogonadotropic hypogonadism secondary to a pituitary deficiency, per the DailyMed Pregnyl label.

For hypogonadotropic hypogonadism in men, that label describes dosing of 500–1,000 USP Units three times weekly for three weeks, then twice weekly; or 4,000 USP Units three times weekly for 6–9 months, reducible to 2,000 USP Units three times weekly (DailyMed). These are label figures, not a Revive protocol — any regimen is determined by a licensed provider.

The uses most men ask about — boosting endogenous testosterone in general hypogonadism, preserving fertility, and serving as a TRT adjunct to limit testicular atrophy — fall outside those two labeled indications and are therefore off-label.

Is hCG FDA-approved? The compounding nuance

This is where accuracy matters. On March 23, 2020, hCG transitioned from being regulated as a drug to a biologic (“deemed to be a license”) under the BPCIA, per an FDA notice to compounders. Because biologics are generally not eligible for 503A/503B compounding, this sharply restricted compounded hCG. A cross-sectional survey found that of 81 FDA-registered 503B outsourcing facilities, only about 5 still supplied compounded hCG (PMC survey).

So: FDA-approved hCG products do exist, but their only labeled male uses are the two above. hCG used for male hypogonadism, fertility, or as a TRT adjunct is compounded and not FDA-approved for those uses — and the FDA has not evaluated compounded hCG for safety, quality, or efficacy. Any availability is provider-determined.

One thing hCG is not for: weight loss. No hCG product is FDA-approved for weight loss, there is no substantial evidence it helps beyond caloric restriction, and OTC or homeopathic hCG weight-loss products are illegal, per an FDA consumer update.

What does the evidence say about hCG’s benefits for men?

Below is a snapshot of the off-label evidence. Note that each figure comes from a specific, often small population and should not be generalized.

Use (off-label)	Key finding	Population / limits
TRT-adjunct fertility preservation	Testosterone alone suppressed intratesticular testosterone (ITT) by 94%; low-dose hCG maintained ITT dose-dependently (125 IU EOD = 25% below baseline; 250 IU = 7% below; 500 IU = 26% above)	RCT, 29 healthy men, 3 weeks (Coviello 2005)
hCG monotherapy (symptomatic, T >300)	Mean total testosterone 361.8 → 519.8 ng/dL (~49.9%, p=0.006); 50% reported symptom improvement	Retrospective series, n=20; no control
hCG monotherapy after prior testosterone	Off-T subset: testosterone ~307 → ~422 ng/dL; estradiol unchanged; no thromboembolic events	Retrospective chart review, 28 men
Fertility in hypogonadotropic hypogonadism	Combined gonadotropin therapy (hCG + FSH) induced spermatogenesis in 86% (95% CI 82–91%) vs 40% (95% CI 25–56%) for hCG alone; pregnancy ~52% (95% CI 42–62%)	Meta-analysis; mean ~12 mo to sperm, ~19 mo to pregnancy

On fertility while on testosterone: in an RCT of 29 men with normal reproductive physiology, 200 mg of testosterone enanthate weekly suppressed intratesticular testosterone by 94%, and adding low-dose hCG preserved it dose-dependently (Coviello 2005, JCEM). This explains why exogenous testosterone can harm fertility and why hCG is sometimes paired with it — but the dose figures are 3-week study findings in healthy volunteers, not a dosing recommendation. Men exploring this pairing may also want to read about hCG with TRT.

For men with symptomatic hypogonadism but baseline testosterone above 300 ng/dL (who may not qualify for TRT), a retrospective series of 20 men using roughly 2000 IU/week saw mean total testosterone rise from 361.8 to 519.8 ng/dL (~49.9%, p=0.006), with 50% reporting symptom improvement (PMC case series). It was small and uncontrolled, so individual results vary.

For fertility in hypogonadotropic hypogonadism specifically, pooled gonadotropin therapy combining hCG with FSH induced spermatogenesis in about 74% of men (95% CI 66–82%) and was more effective than hCG alone, with pregnancy in about 52% of men (95% CI 42–62%) (Andrology meta-analysis). In other words, adding FSH to hCG induced spermatogenesis substantially more often than hCG alone, though the exact rates vary by study and population (Andrology meta-analysis).

How does hCG compare with TRT and enclomiphene?

hCG, testosterone replacement therapy (TRT), and enclomiphene all aim at low-testosterone symptoms by different routes. TRT supplies testosterone directly but suppresses the body’s own production and can impair fertility. hCG stimulates the testes’ own output. Enclomiphene, a SERM, raises LH and FSH from the pituitary; like compounded hCG, it is off-label in men and not FDA-approved (see what is enclomiphene and enclomiphene vs TRT). These are distinct options and should not be blurred together.

Testosterone itself is a DEA Schedule III controlled substance requiring a valid prescription, a diagnosis (symptoms plus two low early-morning testosterone tests), and ongoing monitoring. On February 28, 2025, the FDA issued class-wide labeling changes for testosterone products, adding a blood-pressure warning and removing the boxed cardiovascular warning following the TRAVERSE trial. Those facts apply to testosterone, not to hCG. If you are unsure which path fits, the signs you may need hormone therapy overview is a helpful starting point.

What are the side effects and risks of hCG in men?

The FDA Pregnyl label lists adverse reactions including headache, irritability, restlessness, depression, fatigue, edema, gynecomastia, precocious puberty (pediatric), and pain at the injection site, plus hypersensitivity reactions.

Because hCG raises testosterone — and testosterone can convert to estradiol via aromatization — estrogen-related effects such as breast tenderness or gynecomastia, water retention, and mood changes can occur. In the TRT literature, estradiol above roughly 60 pg/mL is associated with gynecomastia, and a hematocrit of 52% is the AUA action threshold for erythrocytosis; monitoring of hematocrit, PSA, and blood pressure parallels TRT practice (PMC review). Contraindications on the label include prostatic carcinoma or other androgen-dependent neoplasm, precocious puberty, and prior hCG allergy, with caution advised in cardiac or renal disease, epilepsy, migraine, or asthma because androgens may cause fluid retention.

Frequently asked questions

Is hCG FDA-approved for men?

FDA-approved hCG products carry only two male indications: hypogonadotropic hypogonadism due to pituitary deficiency and prepubertal cryptorchidism, per the DailyMed Pregnyl label. Using hCG to boost general testosterone, preserve fertility, or as a TRT adjunct is off-label, and hCG compounded for those uses is not FDA-approved — the FDA has not evaluated compounded hCG for safety, quality, or efficacy.

Does hCG raise testosterone in men?

In one small retrospective series of 20 men with symptomatic hypogonadism but baseline testosterone above 300 ng/dL, hCG monotherapy (~2000 IU/week) raised mean total testosterone from 361.8 to 519.8 ng/dL (about 49.9%, p=0.006), with 50% reporting symptom improvement. That study was small and uncontrolled, so individual results vary and outcomes are provider-determined.

Can hCG help preserve fertility on TRT?

In a randomized controlled trial of 29 healthy men, exogenous testosterone suppressed intratesticular testosterone by 94%, and adding low-dose hCG maintained it dose-dependently — the rationale for pairing hCG with TRT. These are 3-week study findings in healthy volunteers, not a guaranteed outcome or a dosing recommendation. A provider determines whether and how it applies to you.

Is hCG used for weight loss?

No. No hCG product is FDA-approved for weight loss, there is no substantial evidence it works beyond caloric restriction, and the FDA considers OTC and homeopathic hCG weight-loss products illegal. hCG should not be associated with weight loss.

What are the main side effects of hCG in men?

The FDA label lists headache, irritability, restlessness, depression, fatigue, edema, gynecomastia, and injection-site pain, plus hypersensitivity reactions. Because hCG raises testosterone (and thereby estradiol), estrogen-related effects like breast tenderness and water retention can occur. Monitoring of hematocrit, PSA, and blood pressure parallels TRT practice.

Is compounded hCG the same as the FDA-approved product?

No. After hCG was deemed a biologic on March 23, 2020, it became generally ineligible for 503A/503B compounding, and compounded availability fell sharply. Compounded hCG used for hypogonadism, fertility, or as a TRT adjunct is not FDA-approved, and the FDA has not evaluated it for safety, quality, or efficacy.